PerkinElmer (NYSE:PKI) Given “Average” Rating at Wood & Company

Wood & Company reissued their average rating on shares of PerkinElmer (NYSE:PKI) in a report released on Friday, AnalystRatings.com reports. The firm currently has a $49.00 price objective on the medical research company’s stock.

A number of other analysts have also recently commented on the stock. Wolfe Research initiated coverage on shares of Waters in a research report on Thursday, May 30th. They set an underperform rating on the stock. Zacks Investment Research raised shares of Icon from a hold rating to a buy rating and set a $157.00 price target on the stock in a research report on Thursday, May 30th. Raymond James upped their price target on shares of S&P Global from $226.00 to $246.00 and gave the company an outperform rating in a research report on Wednesday, July 10th. Royal Bank of Canada set a $60.00 price target on shares of Masonite International and gave the company a buy rating in a research report on Friday, May 3rd. Finally, Goldman Sachs Group cut shares of TerraForm Power from a neutral rating to a sell rating and set a $12.00 price target on the stock. in a research report on Tuesday, April 9th. They noted that the move was a valuation call. Eleven analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. PerkinElmer currently has an average rating of Hold and a consensus price target of $79.17.

NYSE PKI opened at $93.83 on Friday. The firm has a market capitalization of $10.41 billion, a P/E ratio of 25.99, a price-to-earnings-growth ratio of 1.66 and a beta of 1.26. PerkinElmer has a twelve month low of $71.83 and a twelve month high of $103.00. The firm has a fifty day moving average of $94.17. The company has a quick ratio of 1.17, a current ratio of 1.68 and a debt-to-equity ratio of 0.70.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. The business had revenue of $648.70 million during the quarter, compared to the consensus estimate of $645.38 million. PerkinElmer had a return on equity of 15.98% and a net margin of 8.89%. PerkinElmer’s quarterly revenue was up .7% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. Sell-side analysts anticipate that PerkinElmer will post 4.05 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. PerkinElmer’s dividend payout ratio (DPR) is presently 7.76%.

Several hedge funds have recently added to or reduced their stakes in the company. Crawford Investment Counsel Inc. boosted its position in shares of PerkinElmer by 1.1% during the 1st quarter. Crawford Investment Counsel Inc. now owns 9,860 shares of the medical research company’s stock worth $950,000 after purchasing an additional 110 shares in the last quarter. Mason Street Advisors LLC boosted its position in shares of PerkinElmer by 0.8% during the 1st quarter. Mason Street Advisors LLC now owns 15,807 shares of the medical research company’s stock worth $1,523,000 after purchasing an additional 124 shares in the last quarter. Retirement Systems of Alabama lifted its position in PerkinElmer by 0.3% in the 2nd quarter. Retirement Systems of Alabama now owns 51,726 shares of the medical research company’s stock valued at $4,983,000 after acquiring an additional 134 shares in the last quarter. First Citizens Bank & Trust Co. lifted its position in PerkinElmer by 0.6% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 28,861 shares of the medical research company’s stock valued at $2,780,000 after acquiring an additional 173 shares in the last quarter. Finally, Palmer Knight Co lifted its position in PerkinElmer by 0.3% in the 2nd quarter. Palmer Knight Co now owns 58,521 shares of the medical research company’s stock valued at $5,638,000 after acquiring an additional 179 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Recommended Story: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.